Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1446626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Marta Hernández-García und 15 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Microbial Sensitivity Tests, Drug Resistance, Bacterial, Lipopolysaccharides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas.
Abstract (Originalsprache)
Introduction
Murepavadin is an antimicrobial peptide (AMP) in clinical development that selectively targets Pseudomonas aeruginosa LptD and whose resistance profile remains unknown. We aimed to explore genomic modifications and consequences underlying murepavadin and/or colistin susceptibility.
Methods
To define genomic mechanisms underlying resistance, we performed two approaches: 1) a genome-wide association study (GWAS) in a P. aeruginosa clinical collection (n=496), considering >0.25 mg/L as tentative cut-off of murepavadin acquired resistance; 2) a paired genomic comparison in a subset of 5 isolates and their isogenic murepavadin-resistant mutants obtained in vitro . Lipid-A composition, immunogenicity and cathelicidin and indolicidin effects on bacterial growth were also tested in this last subset of isolates. Murepavadin MICs were determined in Δ lpxL1 and Δ lpxL2 knock-out mutants obtained from a auxotroph PAO1 derivative.
Results
GWAS revealed a missense variant (A→G p.Thr260Ala in the hisJ gene) associated with murepavadin resistance although both resistant and susceptible strains harbored it (21% and 12% respectively, OR=1.92, p=0.012 in χ² test). Among the isolate subset, murepavadin-resistant mutants with deletions in lpxL1 and lpxL2 genes showed lower abundance of hexa-acylated lipid-A (m/z 1616, 1632). 4-aminoarabinose addition was found only in colistin-resistant isolates but not in the other ones, irrespective of murepavadin susceptibility. Accordingly, Δ lpxL1 and Δ lpxL2 mutants exhibited higher murepavadin MICs than parental PAO1 auxotroph strain (2 and 4 vs 0.5 mg/L respectively). Lipopolysaccharide from murepavadin-resistant mutants triggered lower inflammatory responses in human monocytes. Those with lpxL mutations and hexa-acylated lipid-A loss also exhibited greater growth reduction when exposed to host-derived AMPs cathelicidin and indolicidin.
Discussion
High murepavadin-resistance seems to be linked to lpxL1 and lpxL2 mutations and lower hexa-acylated lipid-A, corresponding to lower inflammatory induction and higher susceptibility to host-derived AMPs. Although GWAS identified one variant associated with the murepavadin-resistant phenotype, data revealed that there was no unique single genetic event underlying this phenotype. Our study provides insight into the mechanisms underlying murepavadin susceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
- CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
- Servicio de Microbiología y Parasitología, Hospital Universitario La Princesa, Madrid, Spain.
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
- Innate Immune Response Group, IdiPAZ, Madrid, Spain.
- Bruker Microbiology & Infection Diagnostics, Bruker Española S.A., Madrid, Spain.
Förderung
- Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas
Zitieren
APA
Hernández-García, M., Barbero-Herranz, R., Bastón-Paz, N., Díez-Aguilar, M., López-Collazo, E., Márquez-Garrido, F. J., Hernández-Pérez, J. M., Baquero, F., Ekkelenkamp, M. B., Fluit, A. C., Fuentes-Valverde, V., Moscoso, M., Bou, G., Del Campo, R., Cantón, R., & Avendaño-Ortiz, J. (2024). Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1446626
Vancouver
Hernández-García M, Barbero-Herranz R, Bastón-Paz N, Díez-Aguilar M, López-Collazo E, Márquez-Garrido FJ, et al. Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1446626
BibTeX
@article{HernndezGarca2024,
author = {Hernández-García, Marta and Barbero-Herranz, Raquel and Bastón-Paz, Natalia and Díez-Aguilar, María and López-Collazo, Eduardo and Márquez-Garrido, Francesc J and Hernández-Pérez, José María and Baquero, Fernando and Ekkelenkamp, Miquel B and Fluit, Ad C and Fuentes-Valverde, Víctor and Moscoso, Miriam and Bou, Germán and Del Campo, Rosa and Cantón, Rafael and Avendaño-Ortiz, José},
title = {Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1446626}
}
EUVIMED